CURRICULUM VITAE Hendrik Peter Nicolas Scholl

October 1, 2013 DEMOGRAPHIC INFORMATION

Current Title and Appointments

Dr. Frieda Derdeyn Bambas Professor of Ophthalmology The Wilmer Eye Institute, Johns Hopkins University Medical School Director, Retinal Degeneration Clinic (Retina Division, Wilmer Eye Institute) Director, Visual Neurophysiology Service (Johns Hopkins Hospital) Co-director of the Johns Hopkins Center for STem Cells and Ophthalmic Regenerative Medicine (STORM)

Personal Data Wilmer Eye Institute Johns Hopkins University 748 Maumenee Building 1800 Orleans Street Baltimore, MD 21287-9277 phone: (443) 287 5495 e-mail: hscholl1@jhmi.edu

Education and Training (in chronological order)

Doctoral/graduate

1989 – 1997 Medical Doctor (Dr. med.), Medical Faculty, University of Tübingen, Germany Thesis: Motion thresholds of colored stimuli of different luminance contrasts are

increased in ocular hypertension and early primary-open-angle-glaucoma 1989 – 1997 Magister Artium (Master of Arts), University of Tübingen (Faculty of Philosophy) Thesis: Remembrance and authenticity. Husserl‘s, Bergson‘s and Heidegger‘s philosophy of time with comments on Proust 1/1/1994 – 5/31/1994 Medical School, Brown University, Providence, Rhode Island, USA Clinical Clerkship: Medicine; Electives: (1) Ophthalmology, (2) Emergency Medicine Postdoctoral

1997 – 2001 Resident in Ophthalmology and Post-Doc Researcher, University Eye Hospital Tübingen Training in anterior and posterior segment clinical ophthalmology Specialized Clinic “Inherited Retinal Dystrophies” Head of the Lab for Cone-type specific Electroretinography 10/1/2001 – 9/30/2003 Clinical Research Fellowship in Medical Retinal Disease, Moorfields Eye Hospital,

London, UK; Research group Prof. Alan C. Bird Research Fellowship of the German Research Foundation (DFG) 1/1/2004 – 12/31/2006 Heisenberg-Fellowship of the German Research Foundation (DFG) “Phenotyping,

genotyping and genotype-phenotype correlation in age-related maculopathy (ARM) and macular degeneration (AMD)”

2

Professional Experience

10/1/2004 – 2/14/2010 Privatdozent (Associate Professor), Medical Faculty, University of Bonn, Germany Consultant Ophthalmologist (Oberarzt), Vitreoretinal Surgeon and Research Coordinator Dept. of Ophthalmology, University of Bonn

Head of the Clinical Electrophysiology Unit (ISCEV standard for Electroretinography, Electro-Oculography, Visual Evoked Potentials)

Head of the Low-Vision-Center 7/31/2006 - 2/14/2010 Coordinator and Supervising Ophthalmologist of the Specialized Clinic Inherited Retinal

and Macular Diseases, Dept. of Ophthalmology, University of Bonn 9/28/2007 – 8/16/2008 Health Management: Advanced training, mibeg-Institute Medicine, Cologne

(www.mibeg.de); Certificate „Health Manager“ (1) Health Care Policy and Economy-related Framework of the Health System; (2)

Commercially-oriented Management; (3) Controlling; (4) Strategic and Organizational Processes in Hospitals; (5) Quality Management; (6) Positioning of Health Care Institutions in the Public; (7) Management Strategies for Physicians-in-Chief

3/1/2008 – 2/14/2010 Head of the Clinical Trial Center of the Dept. of Ophthalmology, Univ. of Bonn „European Vision Institute – Clinical Trials – Sites of Excellence“ (EVI.CT.SE)

3/1/2010 – present Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University Medical School

Director of the Visual Neurophysiology Service (Johns Hopkins Hospital) Director of the Retinal Degeneration Clinic (Retina Division, Wilmer Eye Institute) 12/1/2011 – present The Dr. Frieda Derdeyn Bambas Professor of Ophthalmology (inaugural recipient),

Wilmer Eye Institute, Johns Hopkins University Medical School

RESEARCH ACTIVITIES

Peer Reviewed Original Science Publications

1. The AMD Gene Consortium, Fritsche LG et al. (2013) Seven new loci associated with age-related macular degeneration. Nat Genet. 45: 433-9, 439e1-2.

2. Moshiri A, Scholl HPN, Canto-Soler MV & Goldberg MF (2013) A morphogenetic model for radial streaking in the fundus of the carrier state of X-linked albinism. JAMA Ophthalmol. 131: 691-3.

3. Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HPN (2012) Macular telangiectasia type 2. Prog Retin Eye Res. 34: 49-77.

4. Chen CJ, Scholl HPN, Birch DG, Iwata K, Miller NR, Goldberg MF (2012) Characterizing the phenotype and genotype of a family with occult macular dystrophy. Arch Ophthalmol 130: 1554-9.

5. Fritsche LG, Fleckenstein M, Fiebig BS, Schmitz-Valckenberg S , Almut Bindewald-Wittich A, Keilhauer CN , Renner AB, Mackensen F, Moessner A, Pauleikhoff D, Adrion C, Mansmann U, Scholl HPN, Holz FG (2012) A subgroup of age-related macular degeneration is associated with mono-allelic mutations in the ABCA4 gene. Invest Ophthalmol Vis Sci. 53: 2112-2118.

6. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HPN, Charbel Issa P, Cano M, Brandstätter H, Tsimikas S, Skerka C, Superti-Furga G, Handa JT, Zipfel PF, Witztum JL, Binder CJ (2011) Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478: 76-81.

7. Lauer N, Mihlan M, Hartmann A, Schlötzer-Schrehardt U, Keilhauer C, Scholl HPN, Charbel Issa P, Holz F, Weber BH, Skerka C, Zipfel PF (2011) Complement regulation at necrotic cell lesions is impaired by the age-related macular degeneration-associated factor-h his402 risk variant. J Immunol. 187: 4374-83.

3

8. Finger RP, Fenwick E, Marella M, Charbel Issa P, Scholl HPN, Holz FG, Lamoureux EL (2011) The relative impact of vision impairment and cardiovascular disease on quality of life: The example of Pseudoxanthoma elasticum. Health Qual Life Outcomes. 9(1): 113.

9. Finger RP, Charbel Issa P, Hendig D, Scholl HPN, Holz FG (2011) Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: A one-year prospective study. Am J Ophthalmol. 152: 695-703.

10. Finger RP, Fimmers R, Holz FG, Scholl HPN (2011) Incidence of blindness and severe visual impairment in Germany - projections for 2030. Invest Ophthalmol Vis Sci. 52: 4381-9.

11. Finger RP, Fimmers R, Holz FG, Scholl HPN (2011) Prevalence and causes of registered blindness in the largest federal state of Germany. Brit J Ophthalmol. 95: 1061-7.

12. Finger RP, Charbel Issa P, Schmitz-Valckenberg S, Holz FG, Scholl HPN (2011) Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum. Retina 31: in press.

13. Charbel Issa P, Finger RP, Kruse K, Baumüller S, Scholl HPN, Holz FG (2011) Monthly ranibizumab for non-proliferative macular telangiectasia type 2: A 12-months prospective study: Am J Ophthalmol. 151: 876-886.

14. Troeger E, Sliesoraityte I, Charbel Issa P, Scholl HPN, Zrenner E, Wilke R (2010) An integrated software solution for multi-modal mapping of morphological and functional ocular data. Conf Proc IEEE Eng Med Biol Soc. 2010: 6280-6283.

15. Charbel Issa P, Troeger E, Finger R, Holz FG, Wilke R, Scholl HPN (2010) Structure-function correlation of the human central retina. PLoS One. 22;5(9): e12864.

16. Joshua A Szental JA, Baird PN, Richardson AJ, Islam FMA, Scholl HPN, Charbel Issa P, Holz FG, Gillies M, Guymer RH (2010) Analysis of Glutathione S-Transferase Pi isoform (GSTP1) single nucleotide polymorphisms and macular telangiectasia type 2. Int Ophthalmol. 30: 645-50.

17. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 117: 1134-1146.e3.

18. Charbel Issa P, Finger RP, Götting C, Hendig D, Holz FG, Scholl HPN (2010) Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology. 117:1406-14.

19. Finger RP, Charbel Issa P, Kellner U, Schmitz-Valckenberg S, Fleckenstein M, Scholl HPN, Holz FG. (2010) Spectral domain optical coherence tomography in adult-onset vitelliform macular dystrophy with cuticular drusen. Retina 30: 1455-64.

20. Porz G, Scholl HPN, Holz FG, Finger RP (2010) Methoden zur Ermittlung persönlicher Krankheitskosten am Beispiel retinaler Erkrankungen [Methods for estimating personal costs of disease using retinal diseases as an example.] Ophthalmologe 107: 216-20.

21. Baumüller S, Charbel Issa P, Scholl HPN, Schmitz-Valckenberg S, Holz FG (2010) Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2. Ophthalmology 117: 2162-8.

22. Hecker LA, Edwards AO, Ryu E, Tosakulwong N, Baratz KH, Brown WL, Charbel Issa P, Scholl HPN, Pollok-Kopp B, Schmid-Kubista KE, Bailey KR, Oppermann M (2010) Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet. 19:209-15.

23. Finger RP, Porz G, Fleckenstein M, Charbel Issa P, Lechtenfeld W, Brohlburg D, Scholl HPN, Holz FG (2010) The Retina Hotline – 18 months results from a telephone hotline for patients with retinal diseases. Retina 30:635–639.

24. Scholl HPN, Fleckenstein M, Fritsche LG, Schmitz-Valckenberg S, Göbel A, Adrion C, Herold C, Keilhauer CN, Mackensen F, Mößner A, Pauleikhoff A, Weinberger AWA, Mansmann U, Holz FG, Becker T, Weber BHF (2009) CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. PLoS ONE 4:e7418.

4

25. Finger RP, Charbel Issa P, Ladewig M, Götting C, Holz FG, Scholl HPN (2009) Fundus autofluorescence in patients with pseudoxanthoma elasticum. Retina 29: 1496-505.

26. Gillies MC, Zhu M, Chew E, Barthelmes D, Hughes E, Ali H, Holz FG, Scholl HPN Charbel Issa P (2009) Familial asymptomatic macular telangiectasia type 2. Ophthalmology 116:2422-9.

27. Fleckenstein M, Adrion C, Schmitz-Valckenberg S, Göbel AP, Bindewald-Wittich A, Scholl HPN, Mansmann U, Holz FG for the FAM Study group (2009) Concordance of disease progression in bilateral geographic atrophy due to AMD. Invest Ophthalmol Vis Sci 51: 637-42.

28. Charbel Issa P, Holz FG, Scholl HPN (2009) Metamorphopsia in patients with macular telangiectasia type 2. Doc Ophthalmol. 119:133-40.

29. Helb HM, Charbel Issa P, Fleckenstein M, Schmitz-Valckenberg S, Scholl HPN, Holz FG (2010) Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution, spectral-domain optical coherence tomography. Acta Ophthalmol Scand. 88: 842-9.

30. Charbel Issa P, Finger RP, Holz FG, Scholl HPN (2009) Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterisation of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci. 50: 5913-8.

31. Charbel Issa P, Bolz HJ, Ebermann I, Domeier E, Holz FG, Scholl HPN (2009) Characterization of severe rod-cone dystrophy in a consanguineous family with a splice site mutation in the MERTK gene. Brit J Ophthalmol. 93: 920-5.

32. Schmitz-Valckenberg S, Fleckenstein M, Helb HM, Charbel Issa P, Scholl HPN, Holz FG (2009) In-vivo imaging of foveal sparing in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 50: 3915-21.

33. Charbel Issa P, van der Veen RL, Stijfs A, Holz FG, Scholl HPN, Berendschot TTJM (2009) Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2. Exp Eye Res. 89: 25-31.

34. Fleckenstein M, Charbel Issa P, Fuchs HA, Finger RP, Helb HM, Scholl HPN, Holz FG (2009) Discrete lines of increased fundus autofluorescence in retinal dystrophies and functional correlate on microperimetry. Eye (Lond) 23: 567-75.

35. Charbel Issa P, Scholl HPN, Gaudric A, Massin P, Kreiger AE, Schwartz S, Holz FG (2009) Macular full-thickness and lamellar holes in type 2 idiopathic macular telangiectasia. Eye 23: 435-41.

36. Finger RP, Charbel Issa P, Fimmers R, Holz FG, Rubin GS, Scholl HPN (2008) Reading performance is reduced due to parafoveal scotomas in patients with macular telangiectasia type 2. Invest Ophthalmol Vis Sci. 50: 1366-70.

37. Fleckenstein M, Charbel Issa P, Helb HM, Schmitz-Valckenberg S, Scholl HPN, Holz FG (2008) Correlation of lines of increased autofluorescence in macular dystrophy and pigmented paravenous retinochoroidal atrophy by optical coherence tomography. Arch Ophthalmol. 126:1461-1463.

38. Pauleikhoff D, Scheider A, Wiedmann P, Gelisken F, Scholl HPN, Roider I, Mohr A, Zlateva G, Xu X. (2008) Neovaskuläre altersabhängige Makuladegeneration in Deutschland. Beinträchtigung der Lebensqualität und ihre finanziellen Auswirkungen [Neovascular age-related macular degeneration in Germany: Encroachment on the quality of life and the financial implications.] Ophthalmologe 106: 242-51.

39. Scholl HPN, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Börncke F, Fritsche LG, Chong NV, Fimmers R, Wienker T, Holz FG, Weber BHF, Oppermann M (2008) Systemic complement activation in age-related macular degeneration. PLoS ONE 3(7): e2593.

40. Charbel Issa P, Finger RP, Holz FG, Scholl HPN (2008) Eighteen month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Brit J Ophthalmol 92: 941-5.

41. Helb HM*, Charbel Issa P*, Berendschot TTJM, Scholl HPN, Holz FG (2008) Abnormal Macular Pigment Distribution in Type 2 Macular Telangiectasia. Retina 28: 808-816.

5

42. Fleckenstein M, Charbel Issa P, Helb HM, Schmitz-Valckenberg S, Finger RP, Scholl HPN, Löffler KU, Holz FG (2008) High resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 49: 4137-4144.

43. Finger RP, Charbel Issa P, Ladewig M, Holz FG, Scholl HPN (2008) Intravitreal bevacizumab for choroidal neovascularization associated with Pseudoxanthoma elasticum (PXE). Brit J Ophthalmol. 92: 483-7.

44. Charbel Issa P, Berendschot TTJM, Staurenghi G, Holz FG, Scholl HPN (2008) Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 49: 1172-7.

45. Meyer CH, Scholl HPN, Eter N, Helb HM, Holz FG (2008) Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol. 86: 490-4.

46. Charbel Issa P, Finger RP, Helb HM, Holz FG, Scholl HPN (2008) A new diagnostic approach in patients with type 2 macular telangiectasia: confocal reflectance imaging. Acta Ophthalmol Scand 86:464-5.

47. Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HPN, Holz FG, Eter N. (2008) Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 246:17-25.

48. Charbel Issa P, Helb HM, Holz FG, Scholl HPN (2007) Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia. Am J Ophthalmol. 145:169-175.

49. Charbel Issa P, Helb HM, Rohrschneider K, Holz FG, Scholl HPN (2007) Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci 48: 3788-3795.

50. Charbel Issa P, Holz FG, Scholl HPN (2007) Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 114: 1736-1742.

51. Reinhard J, Messias A, Dietz K, MacKeben M, Lakmann R, Scholl HPN, Apfelstedt-Sylla E, Weber BHF, Seeliger M, Zrenner E, Trauzettel-Klosinski S (2007) Quantifying fixation in patients with Stargardt disease. Vision Research 47: 2076-85.

52. Ebermann I, Walger M, Scholl HPN, Charbel Issa P, Lüke C, Nürnberg G, Lang-Roth R, Becker C, Nürnberg P, Bolz HJ (2007) Truncating mutation of the DFNB59 gene causes endocochlear hearing impairment and central vestibular dysfunction. Hum Mutat. 28: 571-577.

53. Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HPN, Schmitz-Valckenberg S, FAM-Study Group (2007) Progression of Geographic Atrophy and Impact of Fundus Autofluorescence Patterns in Age-related Macular Degeneration. Am J Ophthalmol 143: 463-472.

54. Ebermann I, Scholl HPN, Charbel Issa P, Becirovic E, Lamprecht J, Jurklies B, Millan JM, Aller E, Mitter D, Bolz H (2007) A novel gene for Usher syndrome type 2: mutations in the long isoform of whirlin are associated with retinitis pigmentosa and sensorineural hearing loss. Hum Genet. 121: 203-211.

55. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J, Dreyhaupt J, Wolf S, Scholl HPN, Holz FG for the Fundus Autofluorescence in Age-Related Macular Degeneration Study Group (2006) Correlation between the Area of Increased Autofluorescence Surrounding Geographic Atrophy and Disease Progression in Patients with AMD. Invest Ophthalmol Vis Sci 47: 2648-2654.

56. Scholl HPN, Kremers J, Besch D, Zrenner E, Jägle H (2005) Progressive cone dystrophy with deutan genotype and phenotype. Graefes Arch Clin Exp Ophthalmol 244:183-191.

57. Dandekar SS, Jenkins SA, Peto T, Scholl HPN, Sehmi KS, Fitzke FW, Bird AC, Webster AR (2005) Autofluorescence imaging of choroidal neovascularization due to age-related macular degeneration. Arch Ophthalmol 123: 1507-1513.

58. Scholl HPN, Chong NHV, Robson AG, Holder GE, Moore AT, Bird AC (2004) Fundus autofluorescence in patients with Leber congenital amaurosis. Invest Ophthalmol Vis Sci 45: 2747-2752.

59. Bellmann C, Neveu MM, Scholl HPN, Hogg CR, Rath PP, Jenkins S, Bird AC, Holder GE (2004) Localized retinal electrophysiological and fundus autofluorescence imaging abnormalities in maternal inherited diabetes and deafness. Invest Ophthalmol Vis Sci 45: 2355-2360.

6

60. Scholl HPN, Bellmann C, Dandekar SS, Bird AC, Fitzke FW (2004) Photopic and scotopic fine matrix mapping of retinal areas of increased fundus autofluorescence in patients with age-related maculopathy. Invest Ophthalmol Vis Sci 45: 574-583.

61. Scholl HPN, Dandekar SS, Peto T, Bunce C, Xing W, Jenkins S, Bird AC (2004) What is lost by digitizing stereoscopic fundus color slides for macular grading in age-related maculopathy and degeneration? Ophthalmology 111: 125-132.

62. Scholl HPN, Kremers J (2003) Alterations of L- and M-cone driven ERGs in cone and cone-rod dystrophies. Vision Research 43: 2333-2344.

63. Kremers J, Stepien MW, Scholl HPN, Saito CA (2003) Cone selective adaptation influences L- and M-cone driven signals in electroretinography and psychophysics. Journal of Vision 3: 146-160.

64. Scholl HPN, Kremers J (2003) L- and M-cone driven large-field and multifocal electroretinograms in sector retinitis pigmentosa. Doc Ophthalmol 106: 171-181.

65. Jägle H, Sadowski B, Kremers J, Scholl HPN, Leo-Kottler B, Sharpe LT (2003) Detecting color vision in a malingerer. Doc Ophthalmol 106: 121-128.

66. Scholl HPN, Peto T, Dandekar S, Bunce C, Xing W, Jenkins S, Bird AC (2003) Inter- and intra-observer variability in grading lesions of age-related maculopathy and macular degeneration. Graefes Arch Clin Exp Ophthalmol 241: 39-47.

67. Scholl HPN, Schuster AM, Vonthein R, Zrenner E (2002) Mapping of retinal function in Best macular dystrophy using multifocal electroretinography. Vision Research 42: 1053-1061.

68. Scholl HPN, Besch D, Vonthein R, Weber BHF, Apfelstedt-Sylla E (2002) Alterations of slow and fast rod ERG signals in patients with molecularly confirmed Stargardt disease type 1. Invest Ophthalmol Vis Sci 43: 1248-1256.

69. Scholl HPN, Langrová H, Pusch CM, Wissinger B, Zrenner E, Apfelstedt-Sylla E (2001) Slow and fast rod ERG pathways in patients with X-linked complete stationary night blindness carrying mutations in the NYX gene. Invest Ophthalmol Vis Sci 42: 2728-2736.

70. Kremers J, Scholl HPN (2001) Rod-/L-cone and rod-/M-cone interactions in electroretinograms at different temporal frequencies. Visual Neuroscience 18: 339-351.

71. Scholl HPN, Kremers J (2001) Electroretinograms in S-cone monochromacy using S-cone and rod isolating stimuli. Color Research and Application 26: S136-S139.

72. Scholl HPN, Kremers J, Wissinger B (2001) Macular Dystrophy with protan genotype and phenotype studied with cone type specific ERGs. Current Eye Research 22: 221-228.

73. Scholl HPN, Langrová H, Weber BHF, Zrenner E, Apfelstedt-Sylla E (2001) Clinical electrophysiology of two rod pathways: normative values and clinical application. Graefe's Arch Clin Exp Ophthalmol 239: 71-80.

74. Scholl HPN, Kremers J, Vonthein R, White K, Weber BHF (2001) L- and M-cone driven electroretinograms in Stargardt's macular dystrophy-Fundus flavimaculatus. Invest Ophthalmol Vis Sci 42: 1380-1389.

75. Scholl HPN, Kremers J, Apfelstedt-Sylla E, Zrenner E (2000) L- and M-cone driven ERGs are differently altered in Best's macular dystrophy. Vision Research 40: 3159-3168.

76. Scholl HPN, Kremers J (2000) Large phase differences between L-cone and M-cone driven electroretinograms in retinitis pigmentosa. Invest Ophthalmol Vis Sci 41: 3225-3233.

77. Rivera A, White K, Stohr H, Steiner K, Hemmrich N, Grimm T, Jurklies B, Lorenz B, Scholl HPN, Apfelstedt-Sylla E, Weber BHF (2000) A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration. Am J Hum Genet 67: 800-813.

78. Kremers J, Scholl HPN, Knau H, Berendschot TTJM, Usui T, Sharpe LT (2000) L- and M-cone ratios in human trichromats assessed by psychophysics, electroretinography and retinal densitometry. Journal of the Optical Society of America A 17: 517-526.

79. Kremers J, Usui T, Scholl HPN, Sharpe LT (1999) Cone signal contributions to electroretinograms in dichromats and trichromats. Invest Ophthalmol Vis Sci 40: 920-930.

7

Collaborative Study Publications (Role: Investigator):

80. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 118: 2453-60.

81. Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD; Diabetic Retinopathy Clinical Research Network (2011) Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. Invest Ophthalmol Vis Sci. 52: 6168-73.

82. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 117: 1134-1146.e3.

Peer Reviewed Review Articles

1. Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HPN (2013) Macular telangiectasia type 2. Prog Retin Eye Res. 34: 49-77.

2. Charbel Issa P, Chong NV, Scholl HPN (2011) The significance of the complement system for the pathogenesis of age-related macular degeneration – current evidence and translation into clinical application. Graefe's Arch Clin Exp Ophthalmol 249: 163-74.

3. Finger RP, Krohne TU, Charbel Issa P, Fleckenstein M, Scholl HPN, Holz FG (2009) Plasmapheresis for dry age-related macular degeneration — evidence based? Retina 29: 569-72.

4. Finger RP, Charbel Issa P, Ladewig MS, Götting C, Szliska C, Scholl HPN, Holz FG (2009) Pseudoxanthoma elasticum. Genetics, clinical manifestation and therapeutic approaches. Surv Ophthalmol. 54: 272-285.

5. Schmitz-Valckenberg S, Fleckenstein M, Scholl HPN, Holz FG (2009) Fundus autofluorescence and progression of age-related macular degeneration. Surv Ophthalmol. 54: 96-117.

6. Finger RP, Fleckenstein M, Holz FG, Scholl HPN (2008) Quality of life in age-related macular degeneration – a review of available vision-specific psychometric tools. Qual Life Res. 17: 559-74.

7. Finger RP, Scholl HPN, Holz FG (2008) Patient Reported Outcomes – Relevanz und Anwendung in der Augenheilkunde [Patient reported outcomes. Relevance and application in ophthalmology]. Ophthalmologe 105: 722-726.

8. Scholl HPN, Fleckenstein M, Charbel Issa P, Keilhauer C, Holz FG, Weber BHF (2007) An update on the genetics of age-related macular degeneration. Mol Vis 13: 196-205.

9. Finger RP, Fleckenstein M, Scholl HPN, Holz FG (2007) Pathophysiologie und Therapie der AMD: Therapeutischer Anti-VEGF-Einsatz in der Augenheilkunde [Therapeutic anti-VEGF in ophthalmology: pathophysiology and treatment of age-related macular degeneration]. Pharm Unserer Zeit. 36: 424-430.

10. Ladewig MS, Götting C, Szliska C, Charbel Issa P, Helb HM, Bedenicki I, Scholl HPN, Holz FG (2006) Pseudoxanthoma elasticum. Ophthalmologe 103: 537-551.

11. Ladewig MS, Ziemssen F, Jaissle G, Helb HM, Scholl HPN, Eter N, Bartz-Schmidt KU, Holz FG (2006) Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe 103: 463-470.

12. Zrenner E, Cunha-Vaz J, Sahel JA, Sillito A, Scholl HPN, Wheeler-Schilling TH (2006) The European Vision Institute. Opening up new frontiers?. Ophthalmologe 103:100-103.

13. Scholl HPN, Wheeler-Schilling TH, Zrenner E, Holz FG (2006) Establishing ophthalmology in the research framework programs of the European Union. Ophthalmologe 103:91-99.

8

14. Holz FG, Bindewald-Wittich A, Schmitz-Valckenberg S, Eter N, Scholl HPN (2006) New perspectives in the treatment of age-related macular degeneration. Dtsch Ärztebl C396-401.

15. Holz FG, Helb HM, Bindewald-Wittich A, Scholl HPN (2006) Modern pharmacotherapy of age-related macular degeneration. Internist (Berl) 47:192-198.

16. Scholl HPN, Weber BHF, Nöthen MM, Wienker T, Holz FG (2005) Y402H polymorphism in complement factor H and age-related macula degeneration. Ophthalmologe 102: 1029-1035.

17. Charbel Issa P, Scholl HPN, Holz FG, Oppermann M, Knolle P, Kurts C (2005) The complement system and its possible role in the pathogenesis of age-related macular degeneration. Ophthalmologe 102:1036-1042.

18. Besch D, Jagle H, Scholl HPN, Seeliger MW, Zrenner E (2003) Inherited multifocal RPE-diseases: mechanisms for local dysfunction in global retinoid cycle gene defects. Vision Research 43: 3095-3108.

19. Scholl HPN, Zrenner E (2000) Electrophysiology in the investigation of acquired retinal disorders. Surv Ophthalmol 45: 29-47.

Extramural Sponsorship Current Grants:

3/1/2010 - 2/28/2013 Structure-Function Correlation in Inherited Retinal Degenerations: Development of Surrogate Endpoints for Clinical Trials Wynn-Gund Translational Research Acceleration Program Enhanced Research and Clinical Training Award National Neurovision Research Institute (NNRI) – Foundation Fighting Blindness (FFB) FFB Grant No: NNCD-CL-0310.0049-JHU-WG Total: $510,000 PI: H.P.N. Scholl

1/1/2011 - 12/31/2015 “Ocular Albinism: Structure-Function Correlation of the Central Retina, Phenotype-

Genotype Correlation and Interventional Therapy to Improve Visual Performance” Ocular Albinism Research Fund: # 80026229 Clark Charitable Foundation, Inc. Total: $3,676,000 PI: H.P.N. Scholl

1/1/2012 – 12/31/2015 Baylor-Johns Hopkins Center for Mendelian Genetics

PI: David Valle, M.D. (Hopkins); Co-investigator: James Lupski, M.D., Ph.D. (Baylor) NHGRI/NIH Total: $16,000,000 Collaborator 7/1/2012 - 6/30/2015 The ProgSTAR study (The Natural History of the Progression of Geographic Atrophy

Secondary to Stargardt’s Disease) National Neurovision Research Institute (NNRI) – Foundation Fighting Blindness (FFB) Total: $4,200,000 (Funding to the Wilmer Eye Institute/JHU: $1,343,686) PI: H.P.N. Scholl

2/1/2013 – 1/31/2018 Eye and Vision Genomics Training Program: Institutional Research Training Grants

(T32) for Statistical Genetics and Genome Informatics. PI: Dr. Terri Beaty, Bloomberg School of Public Health, Johns Hopkins University. NIH Grant #: 1T32EY022303-01A1 Total: $800,856 Collaborator/Core Training Faculty Member

9

Pending Investigator in the multi-investigator collaborative Bioengineering Partnership “Computational Model of the Perception of Environments by People with Low Vision” with Johns Hopkins as the lead institution, Exploratory/Developmental Bioengineering Research Grants (EBRG) [R21], NIH PI: Dr. Robert Massof, Wilmer Eye Institute, Johns Hopkins University. Submitted to the NIH

Previous 1/1/2011 - 12/31/2012 Structure-Function Correlation in Macular Degeneration Macular Degeneration Research Award AHAF Grant No: M2010042 American Health Assistance Foundation (AHAF) http://www.ahaf.org/research/grants/mdrcurrentawards.html?page=3

Total: $100,000 PI: H.P.N. Scholl

4/1/2008 - 3/31/2011 Work Package (WP) 2 “The Ageing Eye” European Commission: Collaborative Project “EuroVisionNet” EU FP7 HEALTH-2007-200641 http://www.eurovisionnet.eu/ Total: EUR 795.000 ($1,130,252) / Own Sub-Project (WP2): EUR 58,500 ($83,169) WP Leader: H.P.N. Scholl 10/1/2005 - 2/14/2010 Natural History Study of Macular Telangiectasia Type 2 The Mac Tel Foundation/Lowy Medical Research Institute, Sydney EUR 226,461 ($321,960) PI: F.G. Holz & H.P.N. Scholl Co-PI (50%)

9/1/2008 - 8/31/2009 Complement protein marker for age-related macular degeneration [Komplement-Proteinmarker für die altersabhängige Makuladegeneration]

bonfor O_1370011 Medical Faculty, University of Bonn EUR 62,100 ($39,253) PI: P. Charbel Issa, F.G. Holz & H.P.N. Scholl; Co-PI (33%)

7/1/2009 - 6/30/2011 Molecular diagnostics of AMD [Molekulare Diagnostik der AMD] MODIAMD; BMBF MBT_011

Federal Ministry for Education and Research [Bundesministerium für Bildung und Forschung] BMBF MoBiTech-Initiative

Total: EUR 3,700,000 ($5,260,000) / Own Sub-Project: EUR 500,000 ($710,850) PI: S. Schmitz-Valckenberg, H.P.N. Scholl (until 2/14/2010) & F.G. Holz

1/1/2000 – 12/31/2000 Physiologic and pathophysiologic signal flow of cone types and their interaction in the human electroretinogram [Physiologischer und pathologischer Signalfluß von Zapfentypen und deren Interaktion im Elektroretinogramm (ERG)]

fortüne 707-0-0 Medical Faculty, University of Tübingen) EUR 66,928 ($95,152) PI: H.P.N. Scholl

1/1/2001 – 12/31/2001 Physiologic and pathophysiologic signal flow of cone types and their interaction in the human electroretinogram [Physiologischer und pathologischer Signalfluß von Zapfentypen und deren Interaktion im Elektroretinogramm (ERG)]

fortüne 707-0-1

10

Medical Faculty, University of Tübingen EUR 27,610 ($39,253) PI: H.P.N. Scholl

10/1/2001 - 09/30/2003 DFG Research Fellowship Awarded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) DFG SCHO 734/1 EUR 63,731 ($90,606)

1/1/2004 - 12/31/2006 PHOTAGE „Photoreceptor Dynamics in Age-Related Macular Degeneration. Consequences for early diagnosis“

EU FP5 QLRT-2001-02494 European Commission: Concerted Action Total: EUR 81,600 ($115,158) / Own Sub-Project: EUR 33,600 ($47,769) Coordinator: H.P.N. Scholl

1/1/2004 - 12/31/2006 DFG Heisenberg Fellowship Awarded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) DFG SCHO 734/2 EUR 143,940 ($204,639)

4/1/2005 - 3/31/2009 Work Package (WP) 1 “Phenotyping, tissue and DNA collection in patients with age-related macular disease”

EU FP6 LSHG-CT-2005-512036 European Commission: Integrated Project EVI-GENORET (“Functional Genomics of the Retina in Health and Disease”)

http://www.evi-genoret.org/ Total: EUR 10,000,000 ($14,217,000) / Own Sub-Project (WP2): EUR 206,720 ($293,894) Coordinator: J.A. Sahel

WP1 Leader: H.P.N. Scholl

4/1/2005 – 10/28/2005 International evaluation of the burden of illness of exudative age-related macular degeneration (AMD)

Sponsor: PFIZER, Inc. EUR 1,024 ($1,456) Center Coordinator/PI: H.P.N. Scholl

3/1/2006 – 02/28/2007 Investigation of the complement system in AMD pathogenesis using immunohistochemistry, flow cytometry and serology [Aufklärung der Bedeutung des Komplementsystems für die AMD-Pathogenese mit immunhistologischen, durchflußzytometrischen und serologischen Methoden]

Pro-Re//Seed/Issa.1 Pro Retina Deutschland (Germany) EUR 38,500 ($54,735) PI: P. Charbel Issa, F.G. Holz & H.P.N. Scholl Co-PI (33%)

9/1/2006 – 8/31/2007 Genotype-Phenotype Correlation in geographic atrophy due to age-related macular degeneration [Genotyp-Phänotyp-Korrelation bei AMD-Patienten mit geographischer Atrophie]

German Ophthalmological Society (Deutsche Ophthalmologische Gesellschaft, DOG) EUR 25,000 ($35,543) PI: M. Fleckenstein, H.P.N. Scholl & F.G. Holz Co-PI (33%)

1/1/2007 – 12/31/2007 Microperimetric assessment of patients with Macular Telangiectasia Type 2 Investigator-Initiated Trial (IIT); Sponsor: Dept. of Ophthalmology, University of Bonn;

11

Lowy Medical Research Institute, Sydney EUR 40,000 ($56,868) PI: F.G. Holz & H.P.N. Scholl Co-PI (50%)

1/1/2007 – 12/31/2007 Fundus autofluorescence imaging and macular pigment distribution in Macular Telangiectasia Type 2 Investigator-Initiated Trial (IIT); Sponsor: Dept. of Ophthalmology, University of Bonn; Lowy Medical Research Institute, Sydney

EUR 40,000 ($56,868) PI: F.G. Holz & H.P.N. Scholl Co-PI (50%)

8/1/2007 – 7/31/2008 The complement system in age-related macular degeneration Ernst-Elfriede Griebel Stiftung (Germany) EUR 15,000 ($21,326) PI: P. Charbel Issa, F.G. Holz & H.P.N. Scholl Co-PI (33%)

1/1/2008 – 12/31/2008 Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial) Investigator-Initiated Trial (IIT); Sponsor: Dept. of Ophthalmology, University of Bonn; NOVARTIS, Basel ClinicalTrials.gov # NCT00504400; Paul-Ehrlich-Institut, CRFB002ADE04; EudraCT # 2006-006233-40

EUR 39,6000 ($56,299) PI: F.G. Holz & H.P.N. Scholl Co-PI (50%)

1/1/2008 – 12/31/2008 Ranibizumab to Treat CNVs in Patients With PXE Investigator-Initiated Trial (IIT); Sponsor: Dept. of Ophthalmology, University of Bonn; NOVARTIS, Basel ClinicalTrials.gov # NCT00510965; Paul-Ehrlich-Institut, CRFB002ADE03; EudraCT # 2006-006233-49

EUR 39,6000 ($56,299) PI: F.G. Holz & H.P.N. Scholl Co-PI (50%) Research Program Building / Leadership

7/1/1997 – 9/30/2001 Head of the Laboratory for Cone Type Specific Electroretinography (Dept. of Ophthalmology, University of Tübingen).

10/1/2004 – 2/14/2010 Research Coordinator, Dept. of Ophthalmology, Univ. of Bonn. 10/1/2004 – 2/14/2010 Co-PI of the Research group on Advanced Phenotyping and Genotype-Phenotype

Correlation in Retinal Degenerations at the Dept. of Ophthalmology, University of Bonn. 4/1/2005 – 2/14/2010 PI of the Research group on Genotyping, Phenotyping and Proteomics in Age-related

Macular Degeneration (AMD) in conjunction with the European Integrated Project EVI-GENORET (“Functional Genomics of the Retina in Health and Disease”).

3/1/2008 – 2/14/2010 Head of the Clinical Trial Center of the Dept. of Ophthalmology, Univ. of Bonn „European Vision Institute – Clinical Trials – Sites of Excellence“ (EVI.CT.SE).

3/1/2010 – present Director, Visual Neurophysiology Service, The Johns Hopkins Hospital 3/1/2010 – present PI of the Research Program on Structure-Function Correlation in Retinal and Macular

Degenerations (Foundation Fighting Blindness, American Health Assistance Foundation). 1/1/2011 – present PI of the Research Program on Ocular Albinism (Clark Charitable Foundation, Inc.)

12

1/1/2012 – present Collaborator in the Baylor-Johns Hopkins Center for Mendelian Genetics PI: Dr. David Valle (Johns Hopkins University

PI of the Research Program “The Genetics and Proteomics of Inherited Ophthalmic Diseases” at the Wilmer Eye Institute, Johns Hopkins University

7/1/2012 – present PI of the ProgSTAR study (The Natural History of the Progression of Geographic Atrophy Secondary to Stargardt’s Disease; Collaborative Network of the National Neurovision Research Institute (NNRI)

EDUCATIONAL ACTIVITIES

Educational Publications

Invited review articles 1. Finger RP, Hendig D, Götting C, Charbel Issa P, Zarbock R, Scholl HPN, Holz FG (2011) Patient mit

langjährigem Hochdruck, PAVK und faltigem Hals. Warum muss er unbedingt zum Augenarzt? MMW-Fortschr. Med. 153(7): 38-39.

2. Scholl HPN (2008) Systemische Komplementaktivierung bei der altersabhängigen Makuladegeneration. DZKF 11/12-2008: 53-55.

3. Scholl HPN (2008) Therapeutische Konsequenzen der genetischen Faktoren bei der altersabhängigen Makuladegeneration. Z prakt Augenheilkd 29: 355-358.

4. Scholl HPN (2008) Das Komplementsystem bei der altersabhängigen Makuladegeneration: Von Genen über Proteine zur Therapie. Ophthalmologische Nachrichten 10/2008: in press.

5. Charbel Issa P, Holz FG, Scholl HPN (2008) Systemische Komplementaktivierung bei der altersabhängigen Makuladegeneration. Ophthalmologische Nachrichten 09/2008: 9.

6. Scholl HPN, Fleckenstein M, Schmitz-Valckenberg S, Charbel Issa P, Holz FG (2008) Neue Ansätze zur Diagnostik und Therapie von Netzhauterkrankungen. Augenspiegel 54: 12-16.

7. Schmitz-Valckenberg S, Fleckenstein M, Scholl HPN, Holz FG (2008) Therapieansätze bei atrophischer altersabhängiger Makuladegeneration. Z prakt Augenheilkd 29: in press.

8. Scholl HPN (2008) Die therapeutischen Möglichkeiten bleiben zunächst begrenzt. Stargardtsche Makuladystrophie – Molekulargenetik und Knock-out-Tiermodelle lassen auf Erfolge hoffen. Ophthalmologische Nachrichten 03/2008: 14-16.

9. Fleckenstein M, Finger RP, Charbel Issa P, Scholl HPN, Holz FG (2008) VEGF Trap-Eye. Ein neuer Therapieansatz bei feuchter AMD. Pro Retina Aktuell 107: 3.

10. Finger RP, Scholl HPN, Holz FG (2008) AMD und Lebensqualität. Zum Stellenwert der Prävention und Rehabilitation.. Augenspiegel 54: 10-12.

11. Scholl HPN (2007) Genetische Faktoren der AMD. Ophthalmologische Nachrichten 10/2007: 19-20. 12. Finger RP, Scholl HPN, Holz FG (2007) Intravitreales Ranibizumab zur Therapie von chorioidalen

Neovaskularisationen bei Pseudoxanthoma elasticum. PXE Report 7: 4-5. 13. Finger RP, Scholl HPN, Holz FG (2007) Einsichten in die Erkrankungsentstehung – durch die

Gewebespende. PXE Report 7: 6. 14. Scholl HPN (2007) Genetik der altersabhängigen Makuladegeneration – neue Perspektiven. Z prakt

Augenheilkd 28: 359-361. 15. Scholl HPN, Holz FG (2007) Genetische Faktoren der AMD. Augenspiegel 53: 16-17. 16. Holz FG, Helb HM, Bindewald-Wittich A, Fleckenstein M, Scholl HPN (2006) Pharmakotherapie der

altersabhängigen Makuladegeneration. Z prakt Augenheilkd 26: 265-274.

13

17. Scholl HPN, Fleckenstein M, Krohne T, Helb HM, Charbel Issa P, Holz FG (2006) Interdisziplinärer Dialog beim Pro Retina Research-Colloquium. Augenspiegel 52: 8-10.

18. Charbel Issa P, Scholl HPN, Holz FG (2005) Internationale Studie zu makulären Teleangiektasien. Pro Retina Aktuell 98: 9-10.

Editorials 1. Scholl HPN, Zrenner E (2006) Europäische Forschungsförderung in der Ophthalmologie. Ophthalmologe

103:89-90. 2. Holz FG, Scholl HPN (2005) Komplementfaktor H und die altersabhängige Makuladegeneration. Neue

Erkenntnisse - und Herausforderungen. Ophthalmologe 102:1027-1028.

Case Reports 1. Finger RP, Charbel Issa P, Holz FG, Scholl HPN (2010) A case of diffuse fluorescein leakage not associated

with a CNV in Pseudoxanthoma Elasticum. Eye (Lond) 24: 1111-3. 2. Charbel Issa P, Fleckenstein M, Scholl HPN, Holz FG, Meyer CH (2009) Confocal scanning laser

ophthalmoscopy findings in chronic solar retinopathy. Ophthalmic Surg Lasers Imaging 39:497-499. 3. Charbel Issa P, Foerl M, Helb HM, Scholl HPN, Holz FG (2008) Multimodal fundus imaging in foveal

hypoplasia: combined scanning laser ophthalmoscope imaging and spectral-domain optical coherence tomography. Arch Ophthalmol 126:1463-1465.

4. Charbel Issa P, Scholl HPN, Holz FG (2007) Intravitreal bevacizumab for the treatment of type 2 idiopathic macular telangiectasis. Retinal Cases & Brief Reports 1:79-81.

5. Charbel Issa P, Scholl HPN, Helb HM, Fleckenstein M, Inhetvin-Hutter C, Holz FG (2007) Unilaterale pigmentierte paravenöse retinochorioidale Atrophie [Unilateral pigmented paravenous retinochoroidal atrophy]. Klin Monatsbl Augenheilkd. 224:791-793.

6. Scholl HPN, Thiel HJ, Schlote T (1999) Orbitablutung als Folge einer Heparin-induzierten Thrombozytopenie [Orbital hemorrhage as a sequela of heparin-induced thrombocytopenia]. Klin Monatsbl Augenheilkd 215: 197-200.

Letters, correspondence 1. Finger RP, Krohne TU, Issa PC, Scholl HPN, Holz FG (2010) No evidence to support the use of

plasmapheresis for age-related macular degeneration. Ther Apher Dial. 14: 607-8. 2. Charbel Issa, P, Holz FG, Scholl HPN (2009) Correspondence to: Kovach JL, Rosenfeld PJ (2008)

Bevacizumab (Avastin) therapy for idiopathic macular telangiectasia type 2. Retina 29: 717-8. 3. Charbel Issa, P, Holz FG, Scholl HPN (2008) Juxtafoveal telangiectasis. Ophthalmology 115: 1636.

Book Chapters, Monographs 1. Fletcher EC, Scholl HPN (2013) Ophthalmic disease in the ageing society. In: Scholl HPN, Massof RW,

West SK, eds. Ophthalmology and the Ageing Society (Essentials in Ophthalmology; Singh AD, series editor). Heidelberg New York Dordrecht London: Springer: 1-12.

2. Finger RP, Scholl HPN (2013) Blindness and visual impairment: high-income countries. In: Scholl HPN, Massof RW, West SK, eds. Ophthalmology and the Ageing Society (Essentials in Ophthalmology; Singh AD, series editor). Heidelberg New York Dordrecht London: Springer: 19-32.

14

3. Charbel Issa P, Chong NV, Scholl HPN (2012) The Complement system and age-related macular degeneration. In: Holz FG, Pauleikhoff D, Spaide RF, Bird AC, eds. Age-Related Macular Degeneration. 3rd edition. Berlin Heidelberg New York: Springer: 65-76.

4. Charbel Issa P, Chong NV, Scholl HPN (2011) Das Komplementsystem bei der altersabhängigen Makuladegeneration. In: Die altersabhängige Makuladegeneration. 3. Aufl. Hrsg. von Holz FG, Pauleikhoff D, Spaide RF, Bird AC. Berlin Heidelberg New York: Springer: 65-78.

5. Scholl HPN, Wabbels B (2009) Fundus autofluorescence in Leber congenital amaurosis. In: Lois N & Forrester J, eds. Fundus Autofluorescence Imaging. Lippincott, 175-183.

6. Scholl HPN, Charbel Issa P, Holz FG (2009) Ätiologie und Pathogenese der altersabhängigen Makuladegeneration (AMD). In: Die altersabhängige Makuladegeneration. 2. Aufl. Hrsg. von Eter N. UNI-MED Verlag, Bremen, London, Boston: 13-24.

7. Schmitz-Valckenberg S, Fleckenstein M, Bindewald-Wittich A, Scholl HPN, Holz FG (2009) Fundus autofluorescence in atrophic age-related macular degeneration. In: Lois N & Forrester J, eds. Fundus Autofluorescence Imaging. Lippincott, 131-139.

8. Scholl HPN, Charbel Issa P, Fleckenstein M, Schmitz-Valckenberg S, Holz FG (2009): Age-related Macular Degeneration. In: Encyclopedia of Molecular Mechanisms of Disease. Hrsg. von Lang F. Berlin Heidelberg New York: Springer, 1244-1247.

9. Charbel Issa P, Scholl HPN, Finger RP, Meyer CH, Holz FG (2008) Pharmacotherapy in Macular telangiectasia; In: Nguyen QD, Rodrigues EB, Farah ME, Mieler WF, eds. Retinal Pharmacotherapy, Elsevier, 181-185.

10. Charbel Issa P, Scholl HPN, Finger RP, Meyer CH, Holz FG (2009) Pharmacotherapy in Macular telangiectasia; In: Nguyen QD, Rodrigues EB, Farah ME, Mieler WF, eds. Retinal Pharmacotherapy, Elsevier [in press]

11. Fleckenstein M, Scholl HPN, Holz FG (2007) Discrete lines of increased fundus autofluorescence in various forms of retinal dystrophies. In: Holz FG, Schmitz-Valckenberg S, Spaide RF, Bird AC , eds. Atlas of Fundus Autofluorescence Imaging. Berlin Heidelberg New York: Springer, 121-132.

12. Schmitz-Valckenberg S, Helb HM, Bindewald-Wittich A, Scholl HPN, Holz FG (2007) Age-related macular degeneration II – Geographic atrophy. In: Holz FG, Schmitz-Valckenberg S, Spaide RF, Bird AC , eds. Atlas of Fundus Autofluorescence Imaging. Berlin Heidelberg New York: Springer, 147-163.

13. Charbel Issa P, Scholl HPN, Helb HM, Holz FG (2007) Idiopathic macular telangiectasia. In: Holz FG, Schmitz-Valckenberg S, Spaide RF, Bird AC , eds. Atlas of Fundus Autofluorescence Imaging. Berlin Heidelberg New York: Springer, 199-205.

14. Charbel Issa P, Scholl HPN, Helb HM, Holz FG (2007) Idiopathic macular telangiectasia. In: Holz FG, Spaide RF, eds. Medical Retina. Berlin Heidelberg New York: Springer, 183-197.

15. Schmitz-Valckenberg S, Fleckenstein M, Scholl HPN, Holz FG (2007) New perspectives in geographic atrophy associated with AMD. In: Holz FG, Spaide RF, eds. Medical Retina. Berlin Heidelberg New York: Springer, 114-129.

16. Scholl HPN, Fleckenstein M, Charbel Issa P, Keilhauer C, Holz FG, Weber BHF (2007) Genetics of age-related macular degeneration: update. In: Holz FG, Spaide RF, eds. Medical Retina. Berlin Heidelberg New York: Springer, 35-52.

17. Scholl HPN, Bindewald-Wittich A, Charbel Issa P, Schmitz-Valckenberg S, Holz FG (2006) Ätiologie und Pathogenese der altersabhängigen Makuladegeneration. In: Choroidale Neovaskularisation bei altersabhängiger Makuladegeneration. Hrsg. von Eter N. UNI-MED Verlag, Bremen, London, Boston: 14-25.

18. Eter N, Bindewald-Wittich A, Scholl HPN, Holz FG (2006) Chirurgische Therapie bei altersabhängiger Makuladegeneration. In: Choroidale Neovaskularisation bei altersabhängiger Makuladegeneration. Hrsg. von Eter N. UNI-MED Verlag, Bremen, London, Boston: 72-79.

19. Holz FG, Scholl HPN (2006) Netzhaut: Angewandte Anatomie und klinische Untersuchung. In: Facharztprüfung Augenheilkunde. Hrsg. von Kampik A, Grehn F & Messmer EM. Thieme Verlag, Stuttgart: 115.

15

20. Holz FG, Scholl HPN (2006) Makulafunktionsteste bei trüben Medien. In: Facharztprüfung Augenheilkunde. Hrsg. von Kampik A, Grehn F & Messmer EM. Thieme Verlag, Stuttgart: 115.

21. Holz FG, Scholl HPN (2006) Fluoreszenzangiographie. In: Facharztprüfung Augenheilkunde. Hrsg. von Kampik A, Grehn F & Messmer EM. Thieme Verlag, Stuttgart: 116-117.

22. Scholl HPN, Holz FG (2006) Altersabhängige Makuladegeneration. In: Springer Lexikon Diagnose & Therapie. Springer Medizin Verlag, Heidelberg: 961-966.

23. Bindewald A, Roth F, Schmitz-Valckenberg S, Scholl HPN, Holz FG (2005) Fundus autofluorescence imaging; In: Holz FG, Spaide RF, eds. Medical Retina. Berlin Heidelberg New York: Springer, 19-34.

24. Kremers J, Scholl HPN, Usui T, Zrenner E (1999) Differenzierung unterschiedlicher Zapfensysteme mit dem Elektroretinogramm und Aufdeckung selektiver Schädigungsmuster; In: Zrenner E, ed. Sichtweisen. Entwicklungen in den Jahren 1994-1998. Tübingen: 64-65.

25. Scholl HPN, Zrenner E (1995). Motion thresholds of coloured stimuli of different luminance contrasts are increased in ocular hypertension and early primary-open-angle-glaucoma (POAG). In Drum,B.A. (ed), Colour vision deficiencies XII (pp. 73-85). Dordrecht: Kluwer Academic Publishers.

Whole Books/Textbooks 1. Scholl HPN (1997) Abhängigkeit der Bewegungsempfindlichkeit vom Helligkeitskontrast zweier Farben

beim frühen Glaukom und bei okulärer Hypertension. (Univ. Diss. Tübingen) Knirsch Verlag, Kirchentellinsfurt. (ISBN 3927091375)

2. Scholl HPN (2005) Photoreceptor type-specific electroretinography in inherited retinal disorders. Books on Demand, Norderstedt. (ISBN-10: 3833419709; ISBN-13: 978-3833419706)

3. Scholl HPN, Massof RW, West SK (2013) Ophthalmology and the Ageing Society (Essentials in Ophthalmology; Singh AD, series editor). Heidelberg New York Dordrecht London: Springer. (ISBN-10: 3642363237; ISBN-13: 978-3642363238)

Teaching

Classroom instruction 1997 – 1999 Basic Science Course “Function and Structure of the Visual System” (30%), instructor for

ophthalmologists, Dept. of Pathophysiology of Vision and Neuroophthalmology, University Eye Hospital Tübingen

1997 – 2001 Seminar “Basic Principles of Clinical Electrophysiology of Vision” (10%), instructor for residents, Dept. of Pathophysiology of Vision and Neuroophthalmology, University Eye Hospital Tübingen

1997 – 2001 Seminar “Physiological, Psychophysical and Clinical Aspects of the Visual System” (10%), lecturer for medical students, Dept. of Pathophysiology of Vision and Neuroophthalmology, University Eye Hospital Tübingen

1998 – 2001 Clinical Course “Ophthalmology (Patient Demonstration)”, instructor for medical students, Dept. of Ophthalmology, University of Tübingen

1998 – 2001 Seminar “Color Vision” (20%), lecturer for medical students, Dept. of Pathophysiology of Vision and Neuroophthalmology, University Eye Hospital Tübingen

1998 – 2001 Practical Course “Physiology and Pathophysiology of the Visual System” (20%), instructor for medical students, Department of Experimental Ophthalmology, University of Tübingen

1998 – 2001 Seminar “Inherited Retinal Dystrophies” (40%), lecturer for residents, Dept. of Pathophysiology of Vision and Neuroophthalmology, University Eye Hospital Tübingen

1999 – 2000 Seminar “Physiology of the Retina” (15%), lecturer for residents, Dept. of Pathophysiology of Vision and Neuroophthalmology, University Eye Hospital Tübingen

1999 – 2001 Seminar “The Eye and I – Neural Sciences in Clinical Ophthalmology” (20%), lecturer for

16

residents, Dept. of Ophthalmology, University of Tübingen 1999 – 2001 Core Course “Visual System” (50%), instructor for PhD students, Graduate School of Neural and

Behavioural Sciences, University of Tübingen

2004 – 2010 Practical Course “Principles of Ophthalmic Examination” (15%), lecturer and instructor for medical students, Dept. of Ophthalmology, University of Bonn

2004 – 2010 Lecture Series “Clinical Ophthalmology” (10%), lecturer for medical students, Dept. of Ophthalmology, University of Bonn

2004 – 2010 Core Clinical Course “Clinical Ophthalmology” (10%), instructor for medical students, Dept. of Ophthalmology, University of Bonn

2005 – 2010 Clinical Course “Clinical Ophthalmology II” (15%), instructor for medical students in final year [Praktisches Jahr, PJ], Dept. of Ophthalmology, University of Bonn

2005 – 2008 Course “Experimental Ophthalmology” (30%), instructor for medical students, Dept. of Ophthalmology, University of Bonn

2006 – 2008 Integrated Seminar “Anatomy, Physiology, Ophthalmology” (30%), instructor for (pre-clinical) medical students, University of Bonn

2008 – 2010 Elective “Diagnostics and Therapy of Retinal Diseases” (50%), instructor for medical students, Dept. of Ophthalmology, University of Bonn

2010 – 2012 Residents in Ophthalmology Lecture: “Electrophysiology of retinal disease: a diagnostic and monitoring tool”, Wilmer Eye Institute, Johns Hopkins University.

2010 – 2012 Residents in Ophthalmology Lecture: “Retinal and Macular Dystrophies”, Wilmer Eye Institute, Johns Hopkins University.

2011 – 2012 Residents in Ophthalmology Lecture: “Optical Coherence Tomography – Clinical Application”, Wilmer Eye Institute, Johns Hopkins University; together with Dr. Quan Nguyen.

2011 – present Genes to Society (GTS) program for Johns Hopkins medical students. Lecture: “Age-related Macular Degeneration”

2012 Course “Cellular and molecular biology of photoreceptors in health and disease". Lecture: “Clinical aspects of retinal degeneration”; Seminar: “New therapeutic approaches for retinal degenerations due to mutations of genes implicated in the visual cycle”.

2013 Didactic Course for Residents in Ophthalmology: “Retinal Degenerations and Retinal Dystrophies” (Retina Subspecialty Grand Rounds, Lecture, Seminar); Practical Course in Visual Neurophysiology

Clinical instruction 2004 – 2010 Outpatient service for patients with retinal diseases, including specialized clinics for patients with

age-related macular degeneration and inherited retinal and macular dystrophies. Attending physician, Dept. of Ophthalmology, Univ. of Bonn.

2004 – 2010 Inpatient service Vitreoretinal Surgery. Attending vitreoretinal surgeon, Dept. of Ophthalmology, Univ. of Bonn.

2010 – present Outpatient service: Retinal Degeneration Center, Wilmer Eye Institute, Johns Hopkins Medicine 2010 – present Vitreoretinal Surgery: Wilmer Eye Institute, Johns Hopkins Medicine

Mentoring

Advisees 2005 – 2009 Peter Charbel Issa, MD, clinical fellow, currently Marie Curie Intra-Research Fellow at the

Nuffield Laboratory of Ophthalmology, University of Oxford, UK (Marie Curie Intra-European Fellowship EU-FP7-237238), mentor.

17

2005 – 2010 MD thesis of Arno Göbel: Correlation of progression rate of geographic atrophy due to age-related macular degeneration and genetic variants in the complement factor H and LOC3877715 genes [Korrelation der Progressionsgeschwindigkeit der geographischen Atrophie als Unterform der späten altersabhängigen Makuladegeneration und genetischen Variationen im Komplement Faktor H-Gen und dem LOC387715-Gen], co-mentor.

2006 – 2009 MD thesis of Stefanie Janzer: Investigation of the role of the complement system in the pathogenesis of age-related macular degeneration [Aufklärung der Bedeutung des Komplementsystems für die Pathogenese der altersabhängigen Makuladegeneration mit serologischen Methoden], mentor.

2006 – 2010 Robert P. Finger, MD, MIH, clinical fellow at the Dept. of Ophthalmology, University of Bonn, currently DFG Research Fellow at the Center for Eye Research Australia (CERA; Melbourne, Australia), mentor.

2007 – 2010 MD thesis of Kathrin Kruse: Intravitreal Ranibizumab for macular telangiectaisa type 2 [Intravitreales Ranibizumab zur Behandlung von makulären Teleangiektasien vom Typ 2], mentor.

2011 – present Kristen Bowles, OD, Clinical Research Fellow (previously: National Eye Institute, NIH): Structure-Function Correlation in Stargardt’s Disease – Development of Surrogate Endpoints for Clinical Trials, mentor.

2011 – present Emily Fletcher, MD, Clinical Research Fellow (previously: Oxford University, UK): Structure-Structure-Function and Phenotype Genotype correlation of the central retina in ocular albinism, with interventional therapy to improve visual performance, mentor. Dr. Fletcher is the recipient of the Clinical/Research Fellowship Award in Inherited Orphan Retinal Degenerations 2011 of the Foundation Fighting Blindness.

2011 The Hendrik Scholl Research Grant Award awarded to: Hongting Liu Assessment of Visual Fixation and Central Retinal Sensitivity in Normal Subjects and Subjects

with Maculopathy Using Two Types of Microperimetry Devices Mentor: Hendrik Scholl, Diana Do & Quan Nguyen Sponsor: Hendrik Scholl

2012 – present Rupert W. Strauss, MD, Clinical Research Fellow (previously: Eye Hospital AKH Linz/Dept. of Ophhalmology, Medical University Graz, Austria): The ProgSTAR study (The Natural History of the Progression of Geographic Atrophy Secondary to Stargardt’s Disease), mentor.

2012 – present Yulia Wolfson, MD, Clinical Research Fellow (previously: Department of Ophthalmology, Carmel Medical Center, Haifa, Israel): Interventional Trial in Albinism, mentor.

2013 – present Millena Bittencourt, MD, Clinical Research Fellow: Clinical Trials in Retinal Degenerations, mentor.

2013 – present Rachel Annam, MD, MPH, Clinical Research Fellow (previously: Johns Hopkins Bloomberg School of Public Health): Clinical Trials in Retinal Degenerations, mentor.

2013 – present Voraporn Chaikitmongkol, MD, Clinical Research Fellow (previously: Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand): Visual Neurophysiology, mentor.

Educational Program Building/Leadership 2008 – 2010 Coordinator of the Elective “Diagnostics and Therapy of Retinal Diseases” for medical students,

Dept. of Ophthalmology, University of Bonn

18

Educational Extramural Funding

3/20-21/2009 “The Ageing Eye Conference” European Commission: Collaborative Project “EuroVisionNet” EU FP7 HEALTH-2007-200641

http://www.eurovisionnet.eu/news/news-ageingeye_2009.html; http://www.vision-research.eu/index.php?id=429

EUR 58,500 ($83,169) Organizer and Conference Chair

CLINICAL ACTIVITIES

Certification

Medical, other state/government licensure

1999 – present Baden-Württemberg, Germany 2001 – 2003 General Medical Council, London, United Kingdom, W1W 5JE, UK; GMC No 6035819 2010 – present Medical Licence by Conceded Eminence, Board of Physicians, State of Maryland (D0048402; 4/28/2010 – 9/30/2011) Clinical (Service) Responsibilities 2004 – 2010 Inpatient service Vitreoretinal Surgery, attending vitreoretinal surgeon, Dept. of

Ophthalmology, Univ. of Bonn. 2004 - 2010 Outpatient clinic for Retinal Diseases including Age-related Macular Degeneration,

attending, 1½ days/week, Dept. of Ophthalmology, Univ. of Bonn. 2006 - 2010 Specialized clinic for Inherited Retinal and Macular Diseases, coordinator and

supervising ophthalmologist, 1 day/week, Dept. of Ophthalmology, Univ. of Bonn. 07/2010 – present Head of the Retinal Degeneration Center: Specialized clinic for Inherited Retinal

Degenerations, 2 clinics/week, Wilmer Eye Institute, Johns Hopkins University 07/2010 – present Vitreoretinal Surgery, 1 day/week, Wilmer Eye Institute, Johns Hopkins University 07/2010 – present Director, Retinal Degeneration Clinic (Retina Division, Wilmer Eye Institute) 07/2010 – present Director, Visual Neurophysiology Service (Johns Hopkins Hospital) Clinical Program Building/Leadership

10/1/2004 – 2/14/2010 Head of the Clinical Electrophysiology Unit (ISCEV standard for Electroretinography, Electro-Oculography, Visual Evoked Potentials) of the Dept. of Ophthalmology, University of Bonn.

10/1/2004 – 2/14/2010 Head of the Low Vision Center, Dept. of Ophthalmology, University of Bonn. 7/31/2006 - 2/14/2010 Coordinator and Supervising Ophthalmologist of the Specialized Clinic Inherited Retinal

and Macular Diseases, Dept. of Ophthalmology, Univ. of Bonn. 10/1/2006 - 2/14/2010 Co- Coordinator and Supervising Ophthalmologist of the Specialized Clinic for

Pseudoxanthoma Elasticum. Dept. of Ophthalmology, University of Bonn. 3/1/2008 – 2/14/2010 Head of the Clinical Trial Center of the Dept. of Ophthalmology, Univ. of Bonn

„European Vision Institute – Clinical Trials – Sites of Excellence“ (EVI.CT.SE). 07/2010 – present Director, Retinal Degeneration Clinic (Retina Division, Wilmer Eye Institute) 07/2010 – present Director, Visual Neurophysiology Service (Johns Hopkins Hospital)

19

Clinical Trials (Current)

• A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion; JHU IRB: NA_00071981; Sponsor: Regeneron Pharmaceuticals, Inc.; Principal Investigator: Peter A. Campochiaro, MD: Co-Investigator

• Phase 1b/2a Open-Label, Multiple Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema; JHU IRB: NA_00074750; Sponsor: Ora, Inc, Inc.; Principal Investigator: Peter A. Campochiaro, MD: Co-Investigator

• A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema (Protocol T); JHU IRB: NA_00072168; Sponsor: Diabetic Retinopathy Clinical Research Network (DRCR)/National Institute of Health (NIH); Principal Investigator: Sharon Solomon, MD: Co-Investigator

• A Phase 1, Double Blind, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Subjects with Macular Degeneration; JHU IRB: NA_00073266; Sponsor: Alkeus Pharmaceuticals, Inc.: Principal Investigator

• A Phase 2/3 Randomized, Double-Bllind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP); JHU IRB: NA_00081138; Sponsor: Isis Pharmaceuticals, Inc.; Principal Investigator: Michael Polydefkis, MD: Co-Investigator

• A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the Eye; JHU IRB: NA_00066332; Sponsor: Santen Pharmaceutical Company, Ltd.; Principal Investigator: Peter A. Campochiaro, MD, MSc: Co-Investigator

• An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) (Extension of Study RET IRD 01); JHU IRB: NA_00071649; Sponsor: QLT Phototherapeutics, Inc.: Principal Investigator

• An Open-Label, Phase 1b Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT); JHU IRB: NA_00065438; Sponsor: QLT Phototherapeutics, Inc.: Principal Investigator

• Macular Pigment Optical Density in people with retinal degeneration; JHU IRB: NA_00068353; Sponsor: Foundation Fighting Blindness grant CF-CL-0611-0516-JHU); Ocular Albinism Fund (#80026229), Clark Charitable Foundation Inc.: Principal Investigator

• Structure-Function Correlation in Retinal Degeneration; JHU IRB: NA_00044252; Sponsor: Wynn-Gund Translational Research Acceleration Program Enhanced Research and Clinical Training Award, National Neurovision Research Institute (NNRI) – Foundation Fighting Blindness (FFB; NNCD-CL-0310.0049-JHU-WG), Macular Degeneration Research Award, American Health Assistance Foundation (AHAF; M2010042): Principal Investigator

• Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy - Protocol S. Diabetic Retinopathy Clinical Research Network (DRCR.net); Sponsor: National Eye Institute (NEI/NIH); Principal Investigator: Sharon Solomon, MD: Co-Investigator

20

• Genes in Diabetic Retinopathy Project. Diabetic Retinopathy Clinical Research Network (DRCR.net); Sponsor: National Eye Institute (NEI/NIH): DRCR Chair for Study Coordination and Co-Investigator

• National Ophthalmic Genotyping Network, Stage 1—Creation of Repository for Inherited Ophthalmic Diseases; JHU IRB: NA_00019419; Sponsor: National Eye Institute (NEI/NIH); Principal Investigator: John Gottsch, MD: Co-Investigator

SYSTEM INNOVATION AND QUALITY IMPROVEMENT 2005 – 2008 Quality Management at the Dept. of Ophthalmology, University of Bonn. Quality Management Representative for Research. Certification of the department according to DIN EN ISO 9001 in 2008 http://www.uni-augenklinik.uni-bonn.de/ 2008 – 2010 Clinical Trial Center of the Dept. of Ophthalmology, Univ. of Bonn.

Certified by the European agency „European Vision Institute – Clinical Trials – Sites of Excellence“ (EVI.CT.SE) in 2009 http://www.europeanvisioninstitute.org/CT_SE/index.html

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments 2008 – 2010 Head of the Clinical Trial Center of the Dept. of Ophthalmology, Univ. of Bonn

„European Vision Institute – Clinical Trials – Sites of Excellence“ (EVI.CT.SE) 2010 – 2011 Member of the Search Committee for the Nanotechnology for Eye Faculty Position at

Johns Hopkins. 2011 Member of the Search Committee for the Retina Division (Wilmer Eye Institute, Johns

Hopkins University) Faculty Position at Wilmer Eye Institute for Including National Capitol Region.

2012 Member of two subcommittees of the Wilmer’s Board of Governors initiated End Blindness by the year 2020 Initiative: (1) Wet Age-related Macular Degeneration; (2) Retinal Degenerations and Dry Age-related Macular Degeneration.

2013 Co-Chair of the Search Committee for the Retina Division (Wilmer Eye Institute, Johns Hopkins University) Faculty Position for a fellowship-trained, Board Eligible/Board Certified ophthalmologists specializing in hereditary retinal degenerations.

2013 Co-Chair of the Search Committee for the Retina Division (Wilmer Eye Institute, Johns Hopkins University) Faculty Position for a fellowship-trained, Board Eligible/Board Certified ophthalmologist specializing in retina.

Editorial Activities

Editorial Board Appointments 2013 – present Editorial Board, JAMA Ophthalmology 2012 – present Editorial Board, Translational Vision Science & Technology (TVST) 2006 – 2009 Section Editor, Ophthalmologe

21

Journal Peer-Review Activities (Ad-hoc Reviewer):

Acta Ophthalmologica American Journal of Human Genetics American Journal of Ophthalmology Archives of Ophthalmology Atherosclerosis BMC Medical Genetics BMC Ophthalmology British Journal of Ophthalmology Clinical Ophthalmology Computer Methods and Programs in Biomedicine Documenta Ophthalmologica European Journal of Medical Genetics Experimental Eye Research Expert Reviews in Molecular Medicine Eye (London) Genetics in Medicine Graefe’s Archive for Clinical and Experimental Ophthalmology Human Genetics Indian Journal of Ophthalmology Investigative Ophthalmology and Visual Science Journal of Molecular Pathology Klinische Monatsblätter für Augenheilkunde LANCET Molecular Vision Ophthalmic Genetics Ophthalmic Research Ophthalmologe Ophthalmology PLoS Medicine Proceedings of the National Academy of Sciences (PNAS) RETINA SCIENCE Value in Health

Grant review activities (Ad-hoc Reviewer):

Agence Nationale de la Recherche (ANR - French National Research Agency), General directorate for healthcare provision (DGOS - Ministry of social affairs and health), France Deutsche Forschungsgemeinschaft (DFG – German Research Foundation), Germany Fonds zur Förderung der wissenschaftlichen Forschung (FWF - Austrian Science Fund), Austria Foundation Fighting Blindness (FFB) Medical Research Council (MRC), NIHR Biomedical Research Centre, United Kingdom Wellcome Trust, United Kingdom

22

Professional Societies 1998 – present Association of Research in Vision and Ophthalmology (ARVO; http://www.arvo.org) 1999 – present Deutsche Opthalmologische Gesellschaft [German Ophthalmological Society] (DOG;

http://www.dog.org/) 1999 – 2010 Berufsverband der Augenärzte Deutschlands (BVA; http://www.augeninfo.de/index.php) 2004 – present International Physicians for the Prevention of Nuclear War (IPPNW; http://www.ippnw.org/) 2005 – 2010 Retinologische Gesellschaft (http://www.retinologie.org/) 2011 – present Macula Society (http://www.maculasociety.org/) 2011 – present Retina Society (http://www.retinasociety.org/) Conference Organization (selected) May 2005 Organizer and Chair, Special Interest Group „Phenotyping age-related macular disease (AMD):

Morphology, Imaging and Visual Function” - Joint Meeting of the EVI-GENORET Consortium and the PHOTAGE Group. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, USA.

Feb 2006 Organizer and Chair, Third Annual Meeting of PHOTAGE, Bonn May 2006 Organizer and Chair, Special Interest Group „Immunological factors in the pathogenesis of age-

related macular degeneration”. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, USA.

Oct 2007 Organizer and Chair, Patient Symposium “Age-related Macular Degeneration AMD”. 30. Annual Meeting of PRO RETINA, Neuss (http://www.pro-retina.de/).

Dec 2007 Session Organizer and Chair, „AMD - The challenge of the 21st Century“. EURPEAN VISION SUMMIT, Interlaken, Schweiz (http://www.europeanvisioninstitute.org/summit2007.html).

March 2009 Co-Organizer, 1st Annual Meeting of EuroVisionNet. March 19 2009, Bonn March 2009 Organizer and Chair, The AGEING EYE Conference. March 20-21 2009, Bonn

(http://www.eurovisionnet.eu/news/news-ageingeye_2009.html) July 2009 Co-Organizer, International PXE Workshop “An update on Pseudoxanthoma Elasticum -

Perspectives and future directions”, July 3-4 2009, Bonn (http://www.pxe2009.de/) January 2010 Session Chair: “Retinal Vascular Disease”, Macula 2010, January 23 2010, Johns Hopkins

University School of Medicine, Baltimore. Dec 2010 Session Chair: “Retina”. 23rd Annual Current Concepts in Ophthalmology, Johns Hopkins

University, Baltimore. March 2011 Session Organizer: Imaging I/Imaging II, The 2nd World Congress on Controversies in

Ophthalmology (COPHy), Barcelona, Spain. June 2011 Session Chair: Usher Syndrome, Foundation Fighting Blindness’ national conference, VISIONS,

Baltimore. June 2011 Session Chair: New Horizons in Retina, New Horizons in Retina: Celebrating New

Breakthroughs in Prevention and Treatments with a World-Renowned Faculty, Victor, Idaho. June 2012 Session Chair: “Neovascular AMD”. Age-Related Macular Degeneration in 2012: The Paradigm

Continues to Evolve. Johns Hopkins University, Baltimore. March 2013 Session Chair: “Retina I (Imaging and Genetics)”; “The Future of Retina May Not Be Anti-

VEGF Monotherapy - A Perspective from Industry”, 3rd World Congress on Controversies in Ophthalmology (COPHy), Budapest, Hungary.

23

Consultantships 2005 Easton Associates, L.L.C., New York, USA 2006 – 2008 GENACTIS GmbH, Cologne, Germany 2008 Optherion, Inc., New Haven, USA 2011 – 2012 QLT Inc., Vancouver, BC, Canada from 2011 Member of the Scientific and Advisory Committee of the Institut de la Vision, Paris from 2012 Sanofi- Fovea, Paris, France: Gene Therapy in Stargardt Disease and Usher Syndrome from 2012 StemCells Inc., Newark, California: Data Monitoring Committee for “Phase I/II study of the

safety and preliminary efficacy of HuCNS-SC subretinal transplantation in subjects with geographic atrophy of age-related macular degeneration”

from 2012 Ophthalmic Devices Panel of the Medical Devices Advisory Committee, Food and Drug Administration (FDA), Silver Spring, Maryland, USA

RECOGNITION

Awards, Honors

2001 International Society for Clinical Electrophysiology of Vision (ISCEV) Travel Award Awarded Abstract: Scholl HPN et al. Slow and fast rod ERG pathways in patients with X-linked complete stationary night blindness carrying mutations in the NYX gene. ($600) 2002 Presentation Award of the fortüne/AKF-Colloquium Oct 10th 2002

Awarded Presentation: Scholl HPN & Kremers J, L- and M-cone driven ERGs in cone and cone-rod dystrophies. (EUR 500)

2002 Elfriede-Aulhorn Award of the Neuro-Ophthalmological Society Awarded Paper: Scholl HPN et al. L- and M-cone driven electroretinograms in Stargardt's macular dystrophy-Fundus flavimaculatus. Investigative Ophthalmology & Visual Science. 2001;42:1380-1389. (EUR 5,000)

2003 PHARAMCIA 2003 ARVO Travel Award Awarded Abstract: Scholl HPN et al. Photopic and scotopic fine matrix maping of retinal areas of increased fundus autofluorescence in patients with age-related maculopathy (ARM) and macular degeneration (AMD). Investigative Ophthalmology & Visual Science. 2003 (Suppl);43:5030. (BP 350)

2003 Macula Degeneration Award 2003 of Pro Retina Germany Awarded Papers: (1) Scholl HPN et al. Alterations of slow and fast rod ERG signals in patients with molecularly confirmed Stargardt disease type 1 (STGD1). Investigative Ophthalmology & Visual Science. 2002;43:1248-1256; (2) Scholl HPN et al. Mapping of retinal function in Best macular dystrophy using multifocal electroretinography. Vision Research. 2002;42:1053-1061. (EUR 3,500)

2006 Research Award of the German Ophthalmological Society Awarded Research Work and Proposal: Fleckenstein M, Scholl HPN & Holz FG, Genotype-Phenotype-Correlation in Patients with Geographic Atrophy due to Age-related Macular Degeneration. (EUR 25,000)

2008 KROENER Research Award Awarded Paper: Scholl HPN, Charbel Issa P et al. Systemic complement activation in age-related macular degeneration. PLoS ONE. 2008;3(7): e2593. (EUR 10,000)

2008 European Vision Award 2008 Awarded by the European Vision Institute (http://www.europeanvisioninstitute.org/award_2008-hendrik_scholl.html)

2010 Wynn-Gund Translational Research Acceleration Program Enhanced Research and Clinical Training Award

24

Awarded by the National Neurovision Research Institute – Foundation Fighting Blindness ($510,000)

2010 Macular Degeneration Research Award Awarded by the American Health Assistance Foundation (AHAF)

(http://www.ahaf.org/research/grants/migrated/structure-function.html) ($100,000)

2011 The Dr. Frieda Derdeyn Bambas Professorship of Ophthalmology Wilmer Eye Institute, Johns Hopkins University

2013 Visionary Award Awarded by the Foundation Fighting Blindness (FFB)

2014 ARVO Foundation/Pfizer Ophthalmics Carl Camras Translational Research Award Awarded by the Association for Research in Vision and Ophthalmology (ARVO)

(http://arvo.org/Awards_and_Grants/Awards/2014_Achievement_Award_recipients/) ($10,000)

Invited Lectures (2006-2013)

5/16/2006 “Research in age-related macular degeneration”. AMD Alliance, AMD Global Meeting, Brussels. 5/18-21/2006 (1) “Fundus autofluorescence in age-related macular degeneration”; (2) “Phenotyping AMD in

the EVI-GENORET consortium”. 6th EURETINA Congress, Lisboa. 6/10/2006 “Correlation of CFH Y402H and LOC387715 A69S allele distribution and progression of

geographic atrophy in patients with age-related macular degeneration”. 19th Annual Congress of the German Retina Society and Nordic Vitreoretinal Society, Kiel.

9/1/2006 “Correlation of CFH Y402H and LOC387715 A69S allele distribution and progression of geographic atrophy in patients with age-related macular degeneration”. DFG SPP 1088 Workshop “The Challenge of understanding Age-related Macular Degeneration: Current approaches and Future Research Perspectives”, Bonn.

9/9/2006 “Genetics of retinal disorders”. X. Congress of the International Society of Ocular Toxicology, Königswinter.

9/21-24/2006 (1) “Genetic factors of AMD including complement factor H [Genetische Faktoren der AMD inklusive Komplement Faktor H]”; (2) “Establishing Ophthalmology in the research framework programs of the European Union”.104. Congress of the German Ophthalmological Society, Berlin.

11/2/2006 “New pharmacolog treatments for age-related macular degeneration [Neue medikamentöse Therapien bei der altersabhängigen Makuladegeneration]”. Münchner Ophthalmologisches Curriculum, Munich.

4/27/2007 “Breaking News: Genetic factors in AMD [Genetische Faktoren der AMD]”. Makula-Update 2007, Bonn.

6/12/2007 (1) “Epidemiologic aspects and genetic factors in AMD”; (2) “Functional imaging in age-related macular degeneration”. Joint Congress of SOE /AAO 2007, Vienna.

7/2/2007 “Age-related macular degeneration”. “HEARING AND SEEING: Joined European efforts for fighting sensory disabilities”, Joint Meeting of the EURHEAR and EVI-GENORET consortia, Paris.

9/6/2007 “Complement gene variants and systemic complement protein alterations in AMD”. 4th International Symposium of the German Ophthalmological Society (DOG): Age-Related Macular Degeneration – Pathogenesis and Treatment, Baden-Baden.

25

9/22/2007 “Genetics of AMD – new perspectives [Genetik der AMD – neue Perspektiven]”. 105. Congress of the German Ophthalmological Society, Berlin.

10/5/2007 “Age-related macular degeneration: a genetic, immunologic and systenic disease [Die altersabhängige Makuladegeneration: eine genetische, immunologische und systemische Erkrankung]”. 232. Freiburger Augenärzteabend, University Hospital Freiburg.

10/21/2007 (1) “Microperimetry in Macular Telangiectasia”; (2) “Macular Telangiectasia and Autofluorescence”. MacTel Research Project - Bi-annual Meeting, Sydney.

11/24/2007 “Imaging in Medical Retina”. OPHTHALMOLOGIA BELGICA, Brussels. 11/27/2007 “Genetics of age-related macular degeneration [Die Genetik der altersabhängigen

Makuladegeneration]”. Biologisch-Naturwissen¬schaftl¬iche Sektion, Fortbildungsakademie der Ärztekammer Hamburg, „Komplexe multigene Erkrankungen – Licht am Ende des Tunnels“, Hamburg.

12/4/2007 (1) “The socioeconomic impact of age-related macular degeneration”; (2) “Functional imaging in age-related macular degeneration”. EUROPEAN VISION SUMMIT, Interlaken, Switzerland.

2/8/2008 “Genetics of age-related macular degeneration [Genetik der altersabhängigen Makuladegeneration]”. 170. Versammlung des Vereins Rheinisch-Westfälischer Augenärzte, Wuppertal.

3.7.2008 “Macular Dystrophies [Makuladystrophien]”. Augenärztliche Akademie 2008, Düsseldorf. 3/13/2008 “Genetic advances and therapeutic consequences in AMD”. “Potential therapeutic concepts in

age-related macular degeneration” Meeting, Royal Society of Medicine, London. 3/14/2008 (1) “Retinal imaging and the consequences of findings”; (2) “Complement genes and systemic

complement activation in AMD”. The Amsler Club Meeting, London. 3/28/2008 “Systemic complement activation in AMD”. Pro Retina-Research Colloquium 2008, Potsdam. 4/11/2008 “AMD update: Phenotype-Genotype Correlation and Protein Marker [AMD Update: Phänotyp-

Genotyp-Korrelation und Proteinmarker]”. Makula-Update 2008, Leipzig. 5/17/2008 “Complement inhibition – AMD treatment in the future?” 11th Vitreoretinal Symposium,

Marburg. 7/11/2008 “Current Therapeutic Options for Age-related Macular Degeneration [Aktuelle Therapie der

altersabhängigen Makuladegeneration]”. 40th Course on Retinal Detachment (Wacker-Kurs), Dept. of Ophthalmology, LMU Munich.

9/18-21/2008 (1) “Genetic biomarkers for retinal diseases”; (2) “Therapeutic consequences of the genetic variants in age-related macular degeneration [Therapeutische Konsequenzen der genetischen Faktoren bei der altersabhängigen Makuladegeneration]”; (3) “European networks in ophthalmic research [Europäische Netzwerke in der ophthalmologischen Forschung]”. 106. Congress of the German Ophthalmological Society, Berlin.

10/3/2008 “Genotyping and Phenotyping – Therapeutic consequences for monogenic retinal dystrophies and age-related macular degeneration”. Lecture of the European Vision Awardee at the European Association for Vision and Eye Research (EVER) meeting, Portoroz, Slovenia.

11/1/2008 “Reading Performance in in Macular Telangiectasia Type 2”. MacTel Research Project - Bi-annual Meeting, London.

11/19/2008 “Macular Degeneration [Makuladegeneration]”. UNIVADIS online-WebCast 11/22/2008 “Future Therapeutic Options for Age-related Macular Degeneration [Zukünftige

Therapieoptionen bei der altersabhängigen Makuladegeneration]”. Patient Symposium of Pro Retina Deutschland and LMU, Munich.

3/13/2009 “Macular Dystrophies [Makuladystrophien]”. Augenärztliche Akademie 2009, Düsseldorf. 3/21/2009 “Age-related Eye Diseases: From Genes to Therapy”. The AGEING EYE Conference, Bonn. 5/14/2009 “Identifying Progression of Dry AMD”. 8th EURETINA Congress, Nice.

26

6/26/2009 “Causes of age-related macular degeneration: Role of genetics and inflammation [AMD-Ursachen: Welche Rolle spielen Genetik und Entzündung?]” 22nd Annual Congress of the German Retina Society, Berlin.

7/4/2009 “High-Resolution SD-OCT of Bruch’s Membrane in PXE”. International PXE Workshop, Bonn. 7/17/2009 “Current Therapeutic Options for Age-related Macular Degeneration [Aktuelle Therapie der

altersabhängigen Makuladegeneration]”. 41st Course on Retinal Detachment (Wacker-Kurs), Dept. of Ophthalmology, LMU Munich.

9/24-27/2009 (1) “AMD: A systemic disease with ophthalmic manifestations? [AMD: Eine systemische Erkrankung mit Manifestation am Auge?]”; (2) “Causes and prevention of AMD – current state of the art [Ursachen und Prävention der AMD – Stand der Dinge]”. 107. Congress of the German Ophthalmological Society, Leipzig.

12/3-5/2009 (1) “What Should We Do About Hereditary Retinal Conditions?”; (2) “Management of non-neovascular "dry” AMD”. Current Concepts in Ophthalmology, Johns Hopkins University School of Medicine, Baltimore.

4/9/2010 “Structure-Function Correlation of the Human Central Retina”. Pro Retina-Research Colloquium 2010, Potsdam.

6/6/2010 “Genetics and prevention of AMD”. World Ophthalmology Congress, Berlin. 9/23/2010 US Congress Briefing

hosted by the Alliance for Eye and Vision Research’s (AEVR) Decade of Vision 2010-2020 Initiative, co-hosted by the AMD Alliance International (AMDAI), the Association for Research in Vision and Ophthalmology (ARVO), and the European Vision Institute (EVI) “Age-related Macular Degeneration: From Gene to Therapy” (http://www.eyeresearch.org/naevr_action/AMD2010.html)

11/15-17/2010 WORLD HEALTH ORGANIZATION, Prevention of Blindness & Deafness WHO Consultation on the public health approaches to the management of age-related macular degeneration, Rome, Italy. “AMD management guidelines currently in use”

12/3/2010 “Retinal Degenerations: State-of-the-art Evaluation and Emerging Therapy”. 23rd Annual Current Concepts in Ophthalmology, Johns Hopkins University, Baltimore

12/11/2010 “Vitrectomy for Proliferative Diabetic Retinopathy”, What’s New in Diabetic Retinopathy and Venous Occlusive Disease, Course, Johns Hopkins University School of Medicine, Baltimore.

3/5/2011 “Structure-Function Correlation of the Central Human Retina”. The 2nd World Congress on Controversies in Ophthalmology (COPHy). Catalonia Palace of Congresses, Barcelona, Spain. 6/30-7/2/2011 “Managing Retinal Degenerations in the Next Decade” and “Genetics and Prevention of AMD”,

New Horizons in Retina: Celebrating New Breakthroughs in Preventions and Treatments with a World-Renowned Faculty, 41st Anniversary of the Wilmer Eye Institute Retina Division, Teton Springs Lodge, Victor, Idaho

12/2/2011 “Update on Clinical Trials for Retinal Degenerations”. 24th Annual Current Concepts in Ophthalmology, Johns Hopkins University, Baltimore

3/23/2012 “Autofluorescence: Pros and Cons”. 3rd World Congress on Controversies in Ophthalmology (COPHy), Istanbul, Turkey.

3/29/2012 US Congress Hearing Public Witness hearing of the House Labor, Health and Human Services, and Education (LHHS) Appropriations Subcommittee; Representing the National Alliance for Eye and Vision Research’s (NAEVR) (http://www.eyeresearch.org/naevr_action/Scholl_Testifys_032912.html)

27

6/9/2012 “Update on Autofluorescence and OCT in AMD”. Age-Related Macular Degeneration in 2012: The Paradigm Continues to Evolve. Johns Hopkins University, Baltimore.

9/22/2012 (1) “A state-of-the-art in SD-OCT: Retinal morphology relevant for retinal disease”; (2) “ Genetics of the visual cycle – consequences for supplementation and therapy”. 110. Congress of the German Ophthalmological Society, Berlin.

10/6/2012 “Increased Vision with QLT091001 in Blindness due to Mutations in Retinal Pigment Epithelium-specific Protein 65kDa (RPE65) or Lecithin Retinol Acyltransferace (LRAT)”. 45th Annual Meeting of the Retina Society, Washington D.C.

11/9/2012 “Increased Vision with QLT091001 in Blindness due to Mutations in Retinal Pigment Epithelium-specific Protein 65kDa (RPE65) or Lecithin Retinol Acyltransferase (LRAT). Phase 1b Study in Subjects with Retinitis Pigmentosa”. American Academy of Ophthalmology, Retina Subspecialty Day, Chicago

12/1/2012 “Genetics of the Visual Cycle – Consequences for Supplementation and Therapy”. ART 2012 Meeting: Past – Present Perspectives in Ophthalmology, Vienna

12/7/2012 “Update on Clinical Trials for Retinal Degenerations”. 25th Annual Current Concepts in Ophthalmology, Johns Hopkins University, Baltimore

1/11/2013 “Does the genotype allow to draw conclusions on the AMD phenotype including exudative versus atrophic AMD ?” Macula of Paris 2013, Paris

1/19/2013 “Autofluorescence in Macular Degeneration – Just the Facts”. MACULA 2013, Johns Hopkins University, Baltimore

2/26/2013 “Radial Streaking in the Fundus”. International Retinal Imaging Symposium (IRIS), Jules Stein Eye Institute, Los Angeles

3/13/2012 US Congress Hearing Public Witness hearing of the House Labor, Health and Human Services, and Education (LHHS) Appropriations Subcommittee; Representing the National Alliance for Eye and Vision Research’s (NAEVR) (http://www.eyeresearch.org/naevr_action/Scholl_Testify_FY2014.html)

4/5/2013 “Role of ICG angiography” and “Role of genetics in AMD progression”. 4th World Congress on Controversies in Ophthalmology (COPHy), Budapest, Hungary.